Article
Zidovudine treatment in patients with primary (acute) human immunodeficiency virus type 1 infection: a randomized, double-blind, placebo-controlled trial. DATRI 002 Study Group. Division of AIDS Treatment Research Initiative.
The Journal of infectious diseases - 1 Jul 1998
Niu M T, Bethel J, Holodniy M, Standiford H C, Schnittman S M
Abstract excerpt
A multicenter, double-blind, placebo-controlled trial randomized 28 patients with primary (acute) human immunodeficiency virus (HIV)-1 infection (PHI) to receive zidovudine, 1000 mg daily, or placebo for 24 weeks. At week 48, compared with placebo patients, zidovudine-treated patients had signifi...
Topics
- Adolescent
- Adult
- Anti-HIV Agents
- Blotting, Western
- CD4 Lymphocyte Count
- Double-Blind Method
- Female
- Follow-Up Studies
- Genotype
- HIV Infections
- HIV-1
- Humans
- Male
- Patient Compliance
- Phenotype